Patent ID: 8765777

Claim:
A method for treating a bacterial infection or a viral infection comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor to a subject in need thereof, wherein said tyrosine kinase inhibitor comprises a compound according to the formula: wherein: R 1 is 4-pyrazinyl, 1-methyl-IH-pyrrolyl, amino-, or amino-lower alkyl-substituted phenyl wherein the amino group in each case is free, alkylated, or acylated, 1H-indolyl or 1H-imidazolyl bonded at a five-membered ring carbon atom, or unsubstituted or lower alkyl-substituted pyridyl bonded at a ring carbon atom and unsubstituted or substituted at the nitrogen atom by oxygen; R 2 and R 3 are each independently of the other hydrogen or lower alkyl, one or two of the radicals R 4 , R 5 , R 6 , R 7 , and R 8 are each nitro, fluoro-substituted lower alkoxy or a radical of the formula —N(R 9 )—C(═X)—(Y) n —R 10 ; wherein: R 9 is hydrogen or lower alkyl; X is oxo, thio, imino, N-lower alkyl-imino, hydroximino, or O-lower alkyl-hydroximino; Y is oxygen or the group NH, n is 0 or 1; and R 10 is an aliphatic radical having at least 5 carbon atoms, or an aromatic, aromatic-aliphatic, cycloaliphatic, cycloaliphatic-aliphatic, heterocyclic, or hetero-cyclicaliphatic radical; and the remaining radicals R 4 , R 5 , R 6 , R 7 , and R 8 are each independently of the others hydrogen, lower alkyl that is unsubstituted or substituted by free or alkylated amino, piperazinyl, piperidinyl, pyrrolidinyl or by morpholinyl, or lower alkanoyl, trifluoromethyl, free, etherified, or esterified hydroxy, free, alkylated or acylated amino or free or esterified carboxy; or a pharmaceutically acceptable salt, enantiomer, ester, amide, prodrug, or derivative thereof, or the metabolite structure wherein said bacterial infection is caused by Mycobacterium tuberculosis, Pseudomonas, Chlamydia, Helicobacter pylori, Listeria monocytogenes , or Shigella flexneri.